Literature DB >> 2841485

Mutations in Rous sarcoma virus nucleocapsid protein p12 (NC): deletions of Cys-His boxes.

C Méric1, E Gouilloud, P F Spahr.   

Abstract

Rous sarcoma virus nucleocapsid protein p12 (NC) contains two conserved amino acid motifs, the Cys-His boxes, which constitute potential metal-binding domains. To try to understand the function of NC and of each of its Cys-His boxes during the viral life cycle, particularly in viral RNA packaging, we have used synthetic oligonucleotides to delete precisely either the proximal or the distal box, or both Cys-His boxes. The mutant DNAs were transfected into chicken embryo fibroblasts, and the virions produced in a transient assay were characterized biochemically for production of viral proteins and particles, RNA packaging, and infectivity. The results indicated the following. (i) The deletion of either the proximal or the distal box decreases the amount of viral RNA packaged in the particles and results in incomplete 70S dimer formation. (ii) The deletion of both boxes inhibits viral RNA packaging. (iii) The deletion of the proximal, but not the distal, box suppresses any detectable infectivity, while the deletion of the distal, but not the proximal, box lowers infectivity 100 to 200 times.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2841485      PMCID: PMC253454          DOI: 10.1128/JVI.62.9.3328-3333.1988

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  A procedure for Northern blot analysis of native RNA.

Authors:  E W Khandjian; C Méric
Journal:  Anal Biochem       Date:  1986-11-15       Impact factor: 3.365

2.  Potential metal-binding domains in nucleic acid binding proteins.

Authors:  J M Berg
Journal:  Science       Date:  1986-04-25       Impact factor: 47.728

3.  Standardized and simplified nomenclature for proteins common to all retroviruses.

Authors:  J Leis; D Baltimore; J M Bishop; J Coffin; E Fleissner; S P Goff; S Oroszlan; H Robinson; A M Skalka; H M Temin
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

4.  A conserved cis-acting sequence in the 5' leader of avian sarcoma virus RNA is required for packaging.

Authors:  R A Katz; R W Terry; A M Skalka
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

5.  Localization of RNA tumor virus polypeptides. I. Isolation of further virus substructures.

Authors:  D P Bolognesi; R Luftig; J H Shaper
Journal:  Virology       Date:  1973-12       Impact factor: 3.616

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Amino acid sequence of the T4 DNA helix-destabilizing protein.

Authors:  K R Williams; M B LoPresti; M Setoguchi; W H Konigsberg
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

8.  1H NMR (500 MHz) of gene 32 protein--oligonucleotide complexes.

Authors:  R V Prigodich; J Casas-Finet; K R Williams; W Konigsberg; J E Coleman
Journal:  Biochemistry       Date:  1984-01-31       Impact factor: 3.162

9.  Restriction endonuclease and nucleotide sequence analyses of molecularly cloned unintegrated avian tumor virus DNA: structure of large terminal repeats in circle junctions.

Authors:  R A Katz; C A Omer; J H Weis; S A Mitsialis; A J Faras; R V Guntaka
Journal:  J Virol       Date:  1982-04       Impact factor: 5.103

10.  Characterization of a Rous sarcoma virus mutant defective in packaging its own genomic RNA: biological properties of mutant TK15 and mutant-induced transformants.

Authors:  S Kawai; T Koyama
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

View more
  81 in total

1.  Avian endogenous retrovirus EAV-HP shares regions of identity with avian leukosis virus subgroup J and the avian retrotransposon ART-CH.

Authors:  M A Sacco; D M Flannery; K Howes; K Venugopal
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Identification of residues of the Moloney murine leukemia virus nucleocapsid critical for viral DNA synthesis in vivo.

Authors:  J Gonsky; E Bacharach; S P Goff
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  RNA incorporation is critical for retroviral particle integrity after cell membrane assembly of Gag complexes.

Authors:  Shainn-Wei Wang; Anna Aldovini
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 4.  Features, processing states, and heterologous protein interactions in the modulation of the retroviral nucleocapsid protein function.

Authors:  Gilles Mirambeau; Sébastien Lyonnais; Robert J Gorelick
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

5.  Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus.

Authors:  A Aldovini; R A Young
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

6.  RNA dimerization defect in a Rous sarcoma virus matrix mutant.

Authors:  L J Parent; T M Cairns; J A Albert; C B Wilson; J W Wills; R C Craven
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  Binding of human immunodeficiency virus type 1 (HIV-1) RNA to recombinant HIV-1 gag polyprotein.

Authors:  J Luban; S P Goff
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

8.  A 3' UTR sequence stabilizes termination codons in the unspliced RNA of Rous sarcoma virus.

Authors:  Jason E Weil; Karen L Beemon
Journal:  RNA       Date:  2005-11-21       Impact factor: 4.942

9.  The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions.

Authors:  X Yu; X Yuan; Z Matsuda; T H Lee; M Essex
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

10.  Mutations in human immunodeficiency virus type 1 nucleocapsid protein zinc fingers cause premature reverse transcription.

Authors:  James A Thomas; William J Bosche; Teresa L Shatzer; Donald G Johnson; Robert J Gorelick
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.